Editorial Response: Estimating the True Cost of Amphotericin B
Open Access
- 1 December 1999
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 29 (6) , 1408-1410
- https://doi.org/10.1086/313555
Abstract
Like all other cost centers in the hospital, pharmacies remain under pressure to closely watch and control their direct expenditures. However, drugs have many aKeywords
This publication has 14 references indexed in Scilit:
- Clinical Significance of Nephrotoxicity in Patients Treated with Amphotericin B for Suspected or Proven AspergillosisClinical Infectious Diseases, 1999
- THE COST-EFFECTIVENESS OF LOW-MOLECULAR-WEIGHT HEPARIN VS UNFRACTIONATED HEPARIN IN GENERAL AND ORTHOPAEDIC SURGERY: AN ANALYSIS FOR THE GERMAN HEALTHCARE SYSTEMPharmacological Research, 1999
- Economic Analysis of Low-Dose Heparin vs the Low-Molecular-Weight Heparin Enoxaparin for Prevention of Venous Thromboembolism After Colorectal SurgeryArchives of internal medicine (1960), 1999
- Low-Molecular-Weight Heparins Compared with Unfractionated Heparin for Treatment of Acute Deep Venous Thrombosis: A Cost-Effectiveness AnalysisAnnals of Internal Medicine, 1999
- Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and NeutropeniaNew England Journal of Medicine, 1999
- Risk factors for amphotericin B- induced nephrotoxicityJournal of Antimicrobial Chemotherapy, 1999
- Lipid Formulations of Amphotericin B: Clinical Efficacy and ToxicitiesClinical Infectious Diseases, 1998
- Prognosis of Acute Renal Failure 1975-1995Nephron, 1996
- Efficacy of Unilamellar Liposomal Amphotericin B in Treatment of Pulmonary Aspergillosis in Persistently Granulocytopenic Rabbits: The Potential Role of Bronchoalveolar D-Mannitol and Serum Galactomannan as Markers of InfectionThe Journal of Infectious Diseases, 1994
- Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome)Journal of Antimicrobial Chemotherapy, 1991